ALX Oncology (ALXO) Competitors $1.87 +0.08 (+4.47%) Closing price 04:00 PM EasternExtended Trading$1.80 -0.08 (-4.01%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. PBYI, AVTE, OGI, VOR, SGMT, CRGX, GNFT, ACRS, SOPH, and TRDAShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Puma Biotechnology (PBYI), Aerovate Therapeutics (AVTE), Organigram Global (OGI), Vor Biopharma (VOR), Sagimet Biosciences (SGMT), CARGO Therapeutics (CRGX), GENFIT (GNFT), Aclaris Therapeutics (ACRS), SOPHiA GENETICS (SOPH), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Its Competitors Puma Biotechnology Aerovate Therapeutics Organigram Global Vor Biopharma Sagimet Biosciences CARGO Therapeutics GENFIT Aclaris Therapeutics SOPHiA GENETICS Entrada Therapeutics ALX Oncology (NASDAQ:ALXO) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment. Do insiders and institutionals believe in ALXO or PBYI? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is ALXO or PBYI more profitable? Puma Biotechnology has a net margin of 20.38% compared to ALX Oncology's net margin of 0.00%. Puma Biotechnology's return on equity of 53.15% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -115.67% -84.82% Puma Biotechnology 20.38%53.15%23.51% Which has better earnings and valuation, ALXO or PBYI? Puma Biotechnology has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.20-0.85Puma Biotechnology$230.50M1.06$30.28M$0.984.94 Do analysts rate ALXO or PBYI? ALX Oncology presently has a consensus price target of $3.30, indicating a potential upside of 76.47%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 44.63%. Given ALX Oncology's higher probable upside, research analysts plainly believe ALX Oncology is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ALXO or PBYI? ALX Oncology has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Does the media prefer ALXO or PBYI? In the previous week, ALX Oncology and ALX Oncology both had 3 articles in the media. Puma Biotechnology's average media sentiment score of 1.75 beat ALX Oncology's score of 1.43 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryPuma Biotechnology beats ALX Oncology on 11 of the 14 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.14M$3.11B$5.66B$10.37BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.8521.3275.7526.15Price / SalesN/A454.84560.95125.53Price / CashN/A45.2537.6061.28Price / Book0.879.7412.416.36Net Income-$134.85M-$52.93M$3.29B$270.97M7 Day Performance54.55%3.87%1.26%0.36%1 Month Performance70.00%7.65%3.84%6.37%1 Year PerformanceN/A20.14%61.01%28.46% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.6559 of 5 stars$1.87+4.5%$3.30+76.5%-1.1%$100.14MN/A-0.8540Positive NewsPBYIPuma Biotechnology4.0268 of 5 stars$4.64+3.8%$7.00+50.9%+84.3%$225.16M$230.50M4.73200Positive NewsAVTEAerovate TherapeuticsN/A$7.70-0.8%N/A-88.2%$223.18MN/A-2.5820Positive NewsHigh Trading VolumeOGIOrganigram Global1.303 of 5 stars$1.71+3.0%N/A+0.6%$222.52M$117.47M34.21860Positive NewsVORVor Biopharma0.1914 of 5 stars$1.60-8.0%N/AN/A$220.43MN/A-0.12140News CoverageStock SplitGap DownSGMTSagimet Biosciences3.3321 of 5 stars$6.36-5.9%$25.67+303.6%+163.5%$219.85M$2M-3.488CRGXCARGO Therapeutics1.5434 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116GNFTGENFIT1.6371 of 5 stars$4.26+0.3%$9.00+111.2%-34.4%$212.41M$76.77M0.00120Trending NewsAnalyst ForecastAnalyst RevisionACRSAclaris Therapeutics2.6337 of 5 stars$1.84-5.6%$8.71+373.6%+67.0%$211.25M$18.72M-1.34100SOPHSOPHiA GENETICS1.9407 of 5 stars$3.17+1.6%$8.00+152.4%-15.9%$210.85M$65.17M-7.20520TRDAEntrada Therapeutics2.7598 of 5 stars$5.06-4.2%$25.67+407.2%-62.9%$200.84M$210.78M-2.84110News Coverage Related Companies and Tools Related Companies Puma Biotechnology Competitors Aerovate Therapeutics Competitors Organigram Global Competitors Vor Biopharma Competitors Sagimet Biosciences Competitors CARGO Therapeutics Competitors GENFIT Competitors Aclaris Therapeutics Competitors SOPHiA GENETICS Competitors Entrada Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
